Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Eli Lilly CEO David Ricks, whose company has a coronavirus treatment in Phase 3 of clinical trials, told "Axios on HBO" that it'd be smart to share with other countries rather than going America first.
The big picture: 66% of Americans don't want to share a vaccine right away with the rest of the world if the U.S. gets there first, according to a recent Harris poll, Axios' Sam Baker reported last week.
- Ricks, incoming chair of the industry group PhRMA, told Mike Allen the goal would be to "protect as much of the planet as we can, versus looking after only one country by itself — creating an island, which would be, I think, illusory."
But Ricks made a 2-part case for why that is shortsighted.
- Reason 1: "[I]f an individual country exceeds, let's say there's a category of people ... that have the highest risk and we vaccinate all of them. Should we go to the next category of risk or share it with others who have that same, I think humanitarian principles would say we should share at that point."
- Reason 2: "[W]e have to recognize back to the point on public health that this is a shared risk, not an individual risk. So if in an imaginary world we had protected our risk groups A, B and C, but no one else had protected any of theirs, meaning other countries, we still run the risk of people traveling to the US and infecting more and more people.
Between the lines: Ricks noted that the FDA is using a "low bar" for evaluating COVID-19 vaccines, which he defended as "probably appropriate" because of the urgency of the pandemic.
- "[T]he FDA standard ... for vaccine effectiveness is a 50 percent response, meaning that half the people have an adequate response to retain antibodies and mount their own immune response to the disease without getting sick initially."
The bottom line: "I think the strongest global interest is to vaccinate as many high risk people as possible," Ricks said.